Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Preclinical data presented for SIG-007 in models of Fabry disease

Feb. 18, 2020

FDA approves Twirla contraceptive patch

Feb. 17, 2020

Phase I preliminary data presented for ACTUS-101 in late-onset Pompe disease

Feb. 17, 2020

Eisai to withdraw Belviq from U.S. market

Feb. 14, 2020

Positive preclinical data presented for QPG-1029

Feb. 13, 2020

FDA places clinical hold on the IND submission for LB-001

Feb. 12, 2020

Primary objective met in phase II study of TTP-399 in type 1 diabetes

Feb. 11, 2020

Rezolute initiates phase IIb study of RZ-358 in congenital hyperinsulinism

Feb. 11, 2020

Myovant reports positive one-year data from phase III LIBERTY extension study

Feb. 11, 2020

Blocking bad bone

Feb. 11, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...